HPB and Liver Transplant Unit, Queen Elizabeth Hospital, Birmingham B15 2GW, United Kingdom.
Department of HPB and Liver Transplantation, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham B15 2TH, United Kingdom.
World J Gastroenterol. 2022 May 14;28(18):1996-2007. doi: 10.3748/wjg.v28.i18.1996.
Incidental gallbladder cancer (IGBC) represents 50%-60% of gallbladder cancer cases. Data are conflicting on the role of IGBC diagnosis in oncological outcomes. Some studies suggest that IGBC diagnosis does not affect outcomes, while others that overall survival (OS) is longer in these cases compared to non-incidental diagnosis (NIGBC). Furthermore, some studies reported early tumour stages and histopathologic characteristics as possible confounders, while others not.
To investigate the role of IGBC diagnosis on patients' overall survival, especially after surgical treatment with curative intent.
Retrospective analysis of all patient referrals with gallbladder cancer between 2008 and 2020 in a tertiary hepatobiliary centre. Statistical comparison of patient and tumour characteristics between IGBC and NIGBC subgroups was performed. Survival analysis for the whole cohort, surgical and non-surgical subgroups was done with the Kaplan-Meier method and the use of log rank test. Risk analysis was performed with univariable and multivariable Cox regression analysis.
The cohort included 261 patients with gallbladder cancer. 65% of cases had NIGBC and 35% had IGBC. A total of 90 patients received surgical treatment (66% of IGBC cases and 19% of NIGBC cases). NIGBC patients had more advanced T stage and required more extensive resections than IGBC ones. OS was longer in patients with IGBC in the whole cohort (29 4 mo, < 0.001), as well as in the non-surgical (14 2 mo, < 0.001) and surgical subgroups (29 16.5 mo, = 0.001). Disease free survival (DFS) after surgery was longer in patients with IGBC (21.5 mo 8.5 mo, = 0.007). N stage and resection margin status were identified as independent predictors of OS and DFS. NIGBC diagnosis was identified as an independent predictor of OS.
IGBC diagnosis may confer a survival advantage independently of the pathological stage and tumour characteristics. Prospective studies are required to further investigate this, including detailed pathological analysis and molecular gene expression.
偶发胆囊癌(IGBC)占胆囊癌病例的 50%-60%。关于 IGBC 诊断对肿瘤学结果的作用,数据存在争议。一些研究表明 IGBC 诊断不会影响结果,而另一些研究则表明与非偶发性诊断(NIGBC)相比,这些情况下的总生存(OS)更长。此外,一些研究报告了早期肿瘤分期和组织病理学特征可能是混杂因素,而另一些研究则没有。
研究 IGBC 诊断对患者总生存的影响,特别是在具有治愈意图的手术治疗后。
对 2008 年至 2020 年间在一家三级肝胆中心就诊的所有胆囊癌患者进行回顾性分析。对 IGBC 和 NIGBC 亚组的患者和肿瘤特征进行统计学比较。对全队列、手术和非手术亚组进行 Kaplan-Meier 生存分析和对数秩检验。使用单变量和多变量 Cox 回归分析进行风险分析。
该队列包括 261 例胆囊癌患者。65%的病例为 NIGBC,35%的病例为 IGBC。共有 90 例患者接受了手术治疗(IGBC 病例的 66%和 NIGBC 病例的 19%)。NIGBC 患者的 T 分期较晚,需要更广泛的切除。在全队列(29 4 个月,<0.001)、非手术(14 2 个月,<0.001)和手术亚组(29 16.5 个月,=0.001)中,IGBC 患者的 OS 更长。在 IGBC 患者中,手术后无病生存(DFS)更长(21.5 个月 8.5 个月,=0.007)。N 分期和切缘状态被确定为 OS 和 DFS 的独立预测因素。NIGBC 诊断被确定为 OS 的独立预测因素。
IGBC 诊断可能独立于病理分期和肿瘤特征带来生存优势。需要前瞻性研究进一步探讨这一点,包括详细的病理分析和分子基因表达。